{"organizations": [], "uuid": "91f998540bcae974183669e8924a6a304274b9f4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/polyphor-wellcome-trust-loan/ipo-hopeful-polyphor-gets-wellcome-trust-payment-of-970000-sfr-idUSFWN1RP14F", "country": "US", "domain_rank": 408, "title": "IPO hopeful Polyphor gets Wellcome Trust payment of 970,000 Sfr", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-04-13T13:40:00.000+03:00", "replies_count": 0, "uuid": "91f998540bcae974183669e8924a6a304274b9f4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/polyphor-wellcome-trust-loan/ipo-hopeful-polyphor-gets-wellcome-trust-payment-of-970000-sfr-idUSFWN1RP14F", "ord_in_thread": 0, "title": "IPO hopeful Polyphor gets Wellcome Trust payment of 970,000 Sfr", "locations": [], "entities": {"persons": [{"name": "michael shields", "sentiment": "none"}, {"name": "john miller", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "britain", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ipo", "sentiment": "negative"}, {"name": "wellcome trust", "sentiment": "negative"}, {"name": "wellcome", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, April 13 (Reuters) - Swiss drugmaker Polyphor ( IPO-POLY.S ) has completed a collaboration with Britainâ€™s Wellcome Trust on developing novel antibiotics, it said on Friday, triggering a convertible loan payment of 970,000 Swiss francs ($1.01 million).\nThe payment brings the aggregate loan amount to 2.3 million francs, part of a seeding drug discovery award announced in February 2017. Polyphor, which on Monday announced plans to list shares in Switzerland, said it completed the final milestone of its Wellcome collaboration ahead of schedule.\n$1 = 0.9628 Swiss francs Reporting by John Miller; Editing by Michael Shields\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-13T13:40:00.000+03:00", "crawled": "2018-04-13T10:50:20.005+03:00", "highlightTitle": ""}